Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04949529 · ClinicalTrials.gov registry record
Falls: A Marker of Preclinical AD
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 355
- Enrollment target
NCT04949529: Completed study, sponsored by Washington University School of Medicine.
NCT04949529 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 355 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04949529 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
This longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages of AD; and (2) a hypothesized model of central and peripheral mechanism(s) underlying falls and functional mobility in preclinical stages of AD.
Primary Outcome
Prospective monthly fall reporting was collected using an automated phone/email system. Severity of falls was calculated using a previously published algorithm.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2025-04-30 |
What the finished NCT04949529 record still lists
NCT04949529 is an observational study that tracks outcomes without assigning an intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04949529 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04949529 about?
NCT04949529 is a clinical study titled "Falls: A Marker of Preclinical AD". This longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages of AD; and (2) a hypothesized model of central and peripheral mechanis...
What is the current status of trial NCT04949529?
This trial is currently completed. The enrollment target is 355 participants. The study started on 2019-03-07. Estimated completion is 2025-04-30.
Who is sponsoring clinical trial NCT04949529?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI